Table 2.
Comparison of clinicopathological and genomic characteristics in concurrent and metachronous BBC
| Concurrent | Metachronous | p-value | |||
|---|---|---|---|---|---|
| All patients: 75 | 51 | 24 | |||
| Age | <0.001 | ||||
| N (75) | 51 | 24 | |||
| Mean ± SD | 62.4 ± 14.2 | 45.9 ± 12.4 | |||
| Median | 64.7 | 40.8 | |||
| Min-max | 30-87.5 | 33.2-74.4 | |||
| N mut per case (N=75) | 0.19 | ||||
| Mean ± SD | 1.65 ± 1.64 | 7.3 ± 14.2 | |||
| Median | 3 | 1.5 | |||
| Min-max | 0-6 | 0-56 | |||
| N genes per case (N=75) | 0.23 | ||||
| Mean ± SD | 1.4 ± 1.4 | 4.9 ± 8.9 | |||
| Median | 1 | 1 | |||
| Min-max | 0-6 | 0-33 | |||
| N | % | N | % | ||
| Menopausal status (N=72) | <0.001 | ||||
| Premenopausal | 9 | 18.4 | 17 | 73.9 | |
| Postmenopausal | 39 | 79.6 | 6 | 26.1 | |
| N/A | 1 | 8 | 0 | 0 | |
| Concordant histology (N=75) | 0.25 | ||||
| Yes | 29 | 56.9 | 17 | 70.8 | |
| No | 22 | 43.1 | 7 | 29.2 | |
| Concordant grade (N=75) | 0.84 | ||||
| Yes | 24 | 47 | 13 | 54.2 | |
| No | 19 | 37.3 | 8 | 33.3 | |
| N/A | 8 | 15.7 | 3 | 12.5 | |
| Concordance for in situ (N=75) | 0.12 | ||||
| Yes | 29 | 56.9 | 9 | 37.5 | |
| No | 22 | 43.1 | 15 | 62.5 | |
| Concordant ER/PR status (N=73) | 0.013 | ||||
| Yes | 46 | 92 | 16 | 69.6 | |
| No | 4 | 8 | 7 | 30.4 | |
| Clinical subtype (N=147) | <0.001 | ||||
| ER+(LUMA, LUMB, LUM-HER2 | 92 | 92 | 30 | 63.8 | |
| ER-(HER2-enriched, TNBC) | 8 | 8 | 17 | 36.2 | |
| Both ER/PgR+ vs. both TNBC (N=73) | <0.001 | ||||
| Both ER/PgR+ | 44 | 88 | 11 | 47.8 | |
| Both TNBC | 1 | 2 | 5 | 21.8 | |
| Other | 5 | 10 | 7 | 30.4 | |
| Concordant size (N=63) | 0.78 | ||||
| Yes | 24 | 51.1 | 12 | 54.5 | |
| No | 23 | 48.9 | 10 | 45.5 | |
| Multifocality (N=75) | 0.31 | ||||
| Yes | 13 | 72.5 | 9 | 37.5 | |
| No | 38 | 27.5 | 14 | 58.3 | |
| N/A | 0 | 0 | 1 | 4.2 | |
| TP53 mutations (N=75) | <0.001 | ||||
| Mutated | 12 | 23.5 | 16 | 66.7 | |
| WT | 39 | 76.5 | 8 | 33.3 | |
| PIK3CA mutations (N=75) | 0.62 | ||||
| Mutated | 20 | 39.2 | 8 | 33.3 | |
| WT | 31 | 60.8 | 16 | 66.7 | |
| GATA3 mutations (N=75) | 0.88 | ||||
| Mutated | 7 | 13.7 | 3 | 12.5 | |
| WT | 44 | 86.7 | 21 | 87.5 | |
| MLL3 mutations (N=75) | 0.16 | ||||
| Mutated | 2 | 3.9 | 3 | 12.5 | |
| WT | 49 | 96.1 | 21 | 87.5 | |
| Hypermutated samples (N=75) | <0.001 | ||||
| Hyper | 0 | 0 | 5 | 20.8 | |
| No | 51 | 100 | 19 | 79.2 | |
| Preserved SNPs>90%* (N=64) | 0.1 | ||||
| Yes | 37 | 82.2 | 12 | 63.2 | |
| No | 8 | 17.8 | 7 | 36.8 | |
| Preserved zygocity in>90% of SNPs* (N=64) | 0.042 | ||||
| Yes | 29 | 64.4 | 7 | 36.8 | |
| No | 16 | 35.6 | 12 | 63.2 | |
| T1 vs. T2 stability (N=64) | 0.058 | ||||
| Stable | 26 | 57.8 | 5 | 26.3 | |
| Intermediate | 14 | 31.1 | 9 | 47.4 | |
| Unstable | 5 | 11.1 | 5 | 26.3 | |
N in parentheses: number of patients compared in each case;
*
T1 vs. T2 comparisons.